Skip to main content

Table 3 Outcomes between the mPSL alone and rTM groups after the stabilised IPTW

From: Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

 

mPSL alone group

rTM group

All patients, (n)

2611

190

 In-hospital mortality, n (%)

1990 (76.2)

149 (78.4)

 14-day mortality, n (%)

746 (28.6)

46 (24.2)

 28-day mortality, n (%)

1382 (52.9)

90 (47.4)

 Bleeding eventsa

73 (2.8)

8 (4.2)

 Length of hospital stay (days), median (IQR)

22 (13–42)

27 (14–42)

Survivor, (n)

622

41

 Bleeding eventsa

12 (1.9)

0 (0)

 Length of hospital stay (days), median (IQR)

41 (24–64)

50 (32–78)

  1. IQR interquartile range, mPSL methylprednisolone, rTM recombinant human soluble thrombomodulin
  2. aBleeding events included epistaxis, hemoptysis, pulmonary hemorrhage, subcutaneous hemorrhage, purpura, muscle hemorrhage, hematuria, gastrointestinal bleeding, bloody stool and intracranial hemorrhage